Induction of gastric cancer cell adhesion through transforming growth factor-beta1-mediated peritoneal fibrosis by Lv, Zhi-Dong et al.
RESEARCH Open Access















Background: Peritoneal dissemination is one of the main causes of death in gastric cancer patients. Transforming
growth factor-beta1 (TGF-b1), one of the most potent fibrotic stimuli for mesothelial cells, may play a key role in
this processing. The purpose of this study is to elucidate the effects of TGF-b1 on regulation of gastric cancer
adhesion to mesothelial cells.
Methods: Peritoneal tissues and peritoneal wash fluid were obtained for hematoxylin and eosin staining or ELISA
to measure fibrosis and TGF-b1 levels, respectively. The peritoneal mesothelial cell line, HMrSV5, was used to
determine the role of TGF-b1 in regulation of gastric cancer cell adhesion to mesothelial cells and expression of
collagen, fibronectin, and Smad 2/3 by using adhesion assay, western blot, and RT-PCR.
Results: The data showed that TGF-b1 treatment was able to induce collagen III and fibronectin expression in the
mesothelial cells, which was associated with an increased adhesion ability of gastric cancer cells, but knockdown of
minimal sites of cell binding domain of extracellular matrix can partially inhibit these effects.
Conclusion: Peritoneal fibrosis induced by TGF-b1 may provide a favorable environment for the dissemination of
gastric cancer.
Background
Gastric cancer is a significant health problem in most
developing countries, including China, and is the second
leading cause of cancer death worldwide [1]. The exact
cause of gastric cancer has been elusive and the risk fac-
tors identified to date are variable and include helicobacter
pylori infection, tobacco smoking, alcohol consumption
and unhealthy diet. Gastric cancer usually remains undiag-
nosed until late stages due to asymptomatic or nonspecific
presentation in its early stages; by the time clinical symp-
toms manifest, the cancer has generally metastasized to
other parts of the body [1-4]. Peritoneal carcinomatosis
frequently occurs at the later stages of gastric carcinoma,
especially after surgery [2-4], which refers to the peritoneal
metastatic cascade of gastric cancer and significantly
contributes to gastric cancer-related mortality. To date,
the mechanisms by which gastric carcinoma undergoes
peritoneal carcinomatosis has not yet been specified.
Stephen Paget’s ‘seed and soil’ theory of tumor metas-
tasis may provide a clue useful for further investigation.
This theory stated that the sites where metastasis occurs
are defined not only by the tumor cells (seed) but also by
the local microenvironment of the metastatic site (soil)
[5]. In other words, the specific site of cancer cell metas-
tasis is not simply due to anatomic location of the pri-
mary tumor or proximity to secondary sites but rather, it
involves interactions between tumor cells and the local
microenvironment at the secondary site [6]. Therefore,
peritoneal carcinomatosis may occur as the peritoneal
stroma environment promotes tumor cells to attach to
the peritoneal mesothelium by providing various growth
factors and chemokines that promote tumor metastasis
[7]. This process is established by the interactions
between extracellular matrix associated proteins and
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sponding adhesion molecules from tumor cells [8].
Extracellular matrix(ECM) that contains collagen,
laminin, fibronectin and hyaluronic acid provides ligands
for b1-integrin and CD44 h and is known to participate
in the peritoneal dissemination of cancer cells [9].
Transforming growth factor-b, a family of 25 kDa
homodimeric multifunctional regulatory peptides, pos-
sesses a number of biological functions, including extra-
cellular matrix production and maturation [10]. TGF-b1
is one of the most potent fibrosis stimuli of mesothelial
cells [11]; increasing evidence has suggested that TGF-
b1 can induce synthesis of extracellular matrix proteins
and has been implicated as the key mediator of fibro-
genesis in various tissues [12]. In our previous study, we
demonstrated that the TGF-b1 level in peritoneal lavage
fluid is correlated with peritoneal metastasis of gastric
cancer. Other studies have shown that TGF-b1i sa b l e
to stimulate invasion and adhesion of scirrhous gastric
cancer cells to the peritoneum, resulting in an increase
in peritoneal dissemination of tumor cells [13-16]. How-
ever, little is known about the underlying mechanisms
that regulate this activity. Adhesion polypeptides are
located in the cell binding domain of ECM components,
such as fibronectin, laminin, and collagen, and can bind
to specific cell surface cellular adhesion molecules
(CAM) known as integrins for cell-to-ECM adhesion.
However, the common and characteristic RGD (Arg-
Gly-Asp sequences) have been found to selectively block
the binding of tumor cells to ECM, and to consequently
inhibit metastasis [17].
In this study, we hypothesized that disseminated gas-
tric cancer cells secrete abundant inflammatory factors,
such as TGF-b1, in order to induce peritoneal fibrosis
and production of extracellular matrix to generate a sui-
table microenvironment (peritoneal fibrosis) for their
peritoneal dissemination. We first investigated histo-
pathologic changes in the peritoneum and TGF-b1c o n -
centrations in peritoneal lavage fluid. We then
determined the effects of TGF-b1 on the function of
human peritoneal mesothelial cells (HPMCs) and of
microenvironment changes on the ability of gastric can-




Total Smad-2/3, phosphorylated- Smad2 and phos-
phorylated- Smad3 antibodies, as well as second antibo-
dies were purchased from Santa Cruz Biotechnology
Inc, USA. Calcein-AM was brought from CALBIO-
CHEM, UK. RGD (Arg-Gly-Asp), which is the cell bind-
ing domain of the ECM, were obtained from Sigma
(Osaka, Japan). Dulbecco’s modified Eagle’s medium and
fetal calf serum(FCS) were purchased from GIBCOBRL,
USA. Human TGF-b1w a so b t a i n e df r o mS i g m a ,U S A .
human TGF-b1 ELISA kit (R&D, Minneapolis, MN,
USA). Hematoxylin and eosin and Masson stain kit
(Santa Cruz Biotechnology Inc, USA). Phasecontrast
microscope (Japan Nikon). Spectrofluorometer (Japan
Olympus, Japan) were employed. Other laboratory
reagents were obtained from Sigma, USA.
Cell line and culture
A human peritoneal mesothelial cell line HMrSV5 was
kindly provided by Prof. Youming Peng of the Second
Hospital, Zhongnan University, Changsha, PR China and
Prof. Pierre RONCO, Hospital TENON, Paris, France.
This cell line was established after infection of a fully
characterized primary culture of human peritoneal
mesothelial cells with an amphotropic recombinant ret-
rovirus that encodes SV40 large-T Ag under control of
Moloney virus long terminal repeat. An undifferentiated
human gastric carcinoma cell line, HGC-27, was
obtained from the Cancer Research Institute of Beijing,
PR China, and HSC-39 cell line was derived from the
ascites of a signet ring cell gastric carcinoma, which was
obtained from the Department of Medicine, Kyushu
University, Japan. These cell lines were cultivated in T75
tissue culture flasks in DMEM supplemented with 10%
fetal calf serum, 100 U/ml penicillin, 100 μg/ml strepto-
mycin, 2 mM L-glutamine, and 20 mM hydroxyethyl
piperazine ethanesulfonic acid (HEPES). Cultures were
g r o w na t3 7 ° Ci nah u m i d i f i e d5 %C O 2a n d9 5 %a i r
incubator.
Tissue samples
Human peritoneum tissue samples were obtained from
36 gastric cancer patients and 6 benign disease patients
who underwent surgery in the First Affiliated Hospital
of China Medical University between March 2009 and
October 2009. These tissue specimens were taken from
the lower anterior abdominal wall. No patients had
received any form of radiation or chemotherapy before
surgery. The local institutional review board approved
our protocol for use of patient samples; all patients pro-
vided written informed consent prior to participation in
the study. All histology slides were staged and classified
according to the UICC new TNM staging (7th edition).
The peritoneal tissues were directly obtained from the
surgical suite and immediately fixed in 10% buffered for-
malin and then embedded in paraffin. Sections (5 μm)
were prepared and stained with hematoxylin and eosin
and Masson stain. The thickness of the submesothelial
extracellular matrix was determined after the tissue sec-
tions were hematoxylin and eosin and Masson staining,
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calculated for each section and then the data were
summarized.
ELISA detection of TGF-b1 levels in the peritoneal
lavage fluid
The peritoneal lavage fluid was also collected from each
patient. Briefly, during laparotomy, 100 mL physiological
saline was injected into the right upper quadrant or the
Douglas pouch and approximately 60 mL were retrieved.
The peritoneal lavage sample was immediately centrifuged
at 2000 rpm for 10 min at room temperature, and stored
at -80°C until use. The TGF-b1 levels were then assayed
with a human TGF-b1 ELISA kit according to the manu-
facturer’s instructions. The data on the TGF-b1p r o t e i n
levels were summarized as mean ± SE of each sample.
Semi-quantitative reverse transcription polymerase chain
reaction (RT-PCR)
The cells were grown to subconfluence and then starved
for 15 h in serum-free medium to attain quiescence. After-
wards, the cells were washed twice with PBS and cultured
in either serum-free medium (control) or serum-free plus
2 or 10 ng/mL of TGF-b1 (experimental group) for up to
72 h. Total RNA was isolated from these cells using the
TRIzol reagent according to the manufacturer’si n s t r u c -
tions. One microgram of the total cellular RNA was then
reverse-transcribed into cDNA for PCR amplification
using a kit from Sigma. The primer sequences used for
PCR have been listed in Table 1. Amplification consisted
of an initial 5 min incubation at 95°C and then 30
cycles of amplification using 30 s of denaturation at 95°
C, 30 s at 56°C, and 60 s at 72°C. The final extension
was set for 10 min at 72°C. All data were expressed as
the relative differences between control and treated cells
after normalization to b-actin expression.
Protein extraction and western blotting
After the cells were grown and treated with or without
TGF-b1, total cellular protein was extracted using a lysis
buffer and quantified using protein quantification
reagents from Bio-Rad. Next, 50 μg of the protein were
suspended in 5x reducing sample buffer, boiled for 5
min, electrophoresed on 10% SDS-PAGE gels, and then
transferred to polyvinylidene difluoride membrane by
electroblotting. The membrane was blocked in 1% BSA/
0.05% Tween/PBS solution overnight at 4°C, followed by
incubation with the primary antibody (i.e., mouse mono-
clonal antibodies to either human fibronectin, collagen
III, phosphorylated-Smad 2, 3, or total-Smad 2/3) for 24
h. A horseradish peroxidase-labelled goat anti-mouse
IgG was used as the secondary antibody. The blots were
then developed by incubation in a chemiluminescence
substrate and exposed to X-ray films.
Immunofluorescence staining
The expression of fibronectin in HMrSV5 cells was ana-
lyzed by Immunofluorescence microscopy. In brief, the
cells were cultured on collagen-coated glass cover slips
up to confluency and then fixed in 4% paraformaldehyde
in 20 mM HEPES (pH 7.4) and 150 mM NaCl for 20
min. The glass cover slips were rinsed three times and
permeabilized with 1.2% Triton X-100 for 5 min, rinsed
three times again and then incubated with 1% BSA/
0.05% Tween/PBS for 1 hour. Staining for expression of
fibronectin was carried out with a primary rabbit anti-
body anti-fibronectin (1:200) and then with a secondary
antibody conjugated with FITC. The DNA dye To-PRO-
3 (blue) was used for counterstaining. The stained cells
were mounted and viewed under immunofluorescence
microscope.
Tumor cell adhesion assay
The adhesion ability of gastric cancer cells to mesothe-
lial cells was determined as described previously by
Alkhamesi et al [18]. Briefly, HPMCs were grown in
monolayer in 96-well plates overnight and treated with
recombinant human TGF-b1 (5,10, 20 ng/mL) up to 72
h. Cancer cells were pretreated with or without the
addition of 50 μg/ml RGD and stained with 15 μMo f
calcein AM for 30 min at 37°C and 5% CO2. Afterwards,
these cells (5 × 10
4/well) were added to the 96-well
plates that contained peritoneal mesothelial cells and
incubation occurred for 3 h at 37°C. The plates were
then washed three times with 200 μl of growth medium
to remove the non-adherent tumor cells. The remaining
adherent tumor cells were observed under a fluores-
cence microscope and the total fluorescence in each
well was recorded by a spectrofluorimeter using 485 nm
and 535 nm wavelengths for excitation and emission,
respectively. Another plate was seeded with labeled
tumor cells for 3 h as positive control and its fluores-
cence intensity was considered as 100%. The adhesion
percentage was calculated as follows:
%%  binding 1  




   group positive control /. ()
Table 1 Primers used for semi-quantitative RT-PCR
Primer Sequence Length (bp)
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cancer cells were investigated. The peak adhesion of
these cancer cells was observed after 3 h. For each
group, the assay was performed in triplicate.
Statistical analysis
All data were summarized as mean ± SE, where appro-
priate. The student’s t-test was performed for the com-
parison of control and TGF-b1t r e a t m e n tg r o u p s .
Differences were considered statistically significant when
the p-value was ≤ 0.05.
Results
Histological assessment of fibrosis reaction of the
peritoneal tissues
We first stained and examined the histology of perito-
neal tissues according to different gastric cancer stages
for comparison with benign controls. As shown in
Figure 1, the normal peritoneum consisted of only a
monolayer of mesothelium cells with little connective
tissue and the peritoneum from the patients with early
gastric cancer also showed small amounts of connective
tissue under the mesothelial cells. In contrast, the peri-
toneum from patients with carcinomatosis at stage III
and IV was substantially thickened and contained exten-
sive fibrosis. Most importantly, the peritoneal fibrosis
was also found to occur in the peritonea from stage III
gastric cancer in the absence of carcinomatosis.
Detection of TGF-b1 levels in the peritoneal lavage fluid
We assayed TGF-b1 protein levels in the peritoneal
w a s hf l u i da n df o u n dt h a tT G F - b1 levels were signifi-
cantly higher in those patients with gastric cancer than
those in the control group. Levels were even higher in
washes from patients with stage III or IV gastric cancer
than those with stage I or II (Figure 2).
Upregulation of collagen III and fibronectin expression by
TGF-b1
We next determined whether TGF-b1 can affect extra-
cellular matrix production (such as collagen III and
fibronectin) in HPMCs. We cultivated and treated them
with the recombinant human TGF-b1a n dt h e np e r -
formed semi-quantitative RT-PCR analysis. Our data
showed that TGF-b1 upregulated expression of collagen
III and fibronectin mRNA, as compared to the control
group (p < 0.05) (Figure 3). Furthermore, Western blot
analysis also confirmed this finding at the protein level
(Figure 4). In addition, we use immunofluorescence
microscopy to confirm this protein data (Figure 5);
TGF-b1-treated HPMCs exhibited a fibrillar pattern of
fibronectin-specific proteins after 48 h treatment that
was markedly absent in the controls.
TGF-b1 induction of Smad 2 and 3 phosphorylation in
HPMCs
To determine how TGF-b1 regulates collagen III and
fibronectin expression, we treated HPMCs with 5 ng/ml
of TGF-b1; subsequent western blot analysis showed
that TGF-b1 induced phosphorylation of Smad 2 and 3
starting at 10 min post-treatment and reached a maxi-
mum between 30-60 min, but TGF-b1 did not affect the
total Smad 2 and 3 expression levels (Figure 6).
Induction of gastric cancer cell adhesion to the
mesothelial cells through peritoneal fibrosis
We then assessed the role of peritoneal fibrosis and
RGD (Arg-Gly-Asp sequences) in regulating the adhe-
sion ability of gastric cancer cells to mesothelial cells.
Through fluorescently examining the level of tumor
cells adhering to mesothelial cells in response to TGF-
b1 treatment, we found that peritoneal fibrosis appeared
to be able to promote gastric cancer cell adherence to
mesothelial cells in a TGF-b1 dose-dependent manner,
as compared to the control (p <0 . 0 5 ) .R G Dd e c r e a s e d
the number of cancer cells to adhere to the mesothelial
cells under TGF-b1 stimulation (Figure 7). The data on
cancer cells obtained from ascites or no-ascites also
showed similar results.
Discussion
In the current study, we first assessed the histology of
peritoneal tissues and detected the TGF-b1l e v e l si n
peritoneal wash fluids obtained from patients with gas-
tric cancer and benign disease. After that, we deter-
mined the role of TGF-b1 in promotion of collagen III
and fibronectin expression and then performed tumor
cell adhesion assay to identify the effects of TGF-b1o n
the mesothelial cells, as well as on Smad 2 and 3 expres-
sion. We found that the peritoneum was significantly
thickened in gastric cancer patients and consisted of
extensive fibrosis; in addition, TGF-b1 levels were also
dramatically increased in peritoneal wash fluid from
stage III or IV gastric cancer compared to that from
stage I and II gastric cancer and benign disease. TGF-
b1-treated mesothelial cells exhibited increased collagen
III and fibronectin expression and promoted gastric can-
cer cells adherence to mesothelial cells. It has been
hypothesized that the effects of TGF-b1m a yb e
mediated by induction of Smad 2 and 3 phosphorylation
in the mesothelial cells. The data from the current study
indicate that induction of peritoneal fibrosis by TGF-b1
may provide a suitable environment for the dissemina-
tion of gastric cancer. The interaction of gastric cancer
with peritoneal mesothelial cells could provide the theo-
retical ‘seed’ and ‘soil’ to promote gastric cancer metas-
tasis to the peritoneum.
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unique position to metastasize to the peritoneum, due to
its ability to readily physically invade into the peritoneal
cavity. However, a more complicated process may be
involved. For example, the peritoneal microenvironment
may also favor implantation of gastric cancer cells on the
peritoneal lining [7]. Attachment of malignant cells to the
peritoneal mesothelium is thought to be a critical step in
peritoneal dissemination of the disease [19]. Previous stu-
dies have suggested that this process was mediated by
interaction between extracellular matrix and the corre-
sponding adhesion molecules from gastric cancer cells
[20]. Moreover, the extracellular matrix may serve to
anchor the cancer cells [9]. Indeed, our current study has
demonstrated such an interaction and showed that TGF-
b1 promoted the peritoneal fibrosis that in turn provided
as u i t a b l e‘soil’ for metastasis. We found that the perito-
neum from patients with stage III and IV gastric cancer
and peritoneal carcinomatosis was thickened and con-
sisted of extensive fibrosis and mass stroma cell infiltra-
tion. Most importantly, fibrosis also occurred in the
peritonea from the stage III gastric cancer tissues even in
the absence of carcinomatosis, indicating that this perito-
neal fibrosis did not depend on tumor presence but
instead may have been promoted by inflammatory factors,
such as TGF-b1, secreted by gastric cancer cells [21].
The cause of peritoneal fibrosis in gastric cancer
patients has been investigated previously, and TGF-b1
was identified as one of the most potent fibrotic stimuli
for mesothelial fibrosis [22,23]. For example, our pre-
vious study showed that TGF-b1 expression in gastric
cancer tissues was closely associated with the depth of
Figure 1 Hematoxylin and eosin and Masson staining of peritoneum tissues. Normal peritoneum and peritoneum from different stages of
gastric cancer were obtained surgically and subjected to H&E and the Masson staining. A, All photos were obtained at 40 × magnification. a
and e, The normal peritoneum consists of only a monolayer of mesothelium with little fibrosis (arrows). b and f, Peritoneum from the patients
with early gastric cancer also showed small amounts of connective tissue under the mesothelial cells. In contrast, the peritoneum from patients
with carcinomatosis at stage III (c, g) and IV (d, h) was substantially thickened and contained extensive fibrosis (arrows). B, Morphometric
parameters of peritoneal tissues. Data are expressed as the mean ± standard error of the mean of at least 3 separate experiments.
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of gastric cancer. But, it was unclear how TGF-b1
induced gastric cancer cell invasion and metastasis to
the peritonea. Our current study indicated that the
induced TGF-b1 level observed in the peritoneal wash
fluid could play a key role in promoting peritoneal fibro-
sis and create a suitable environment for gastric cancer
metastasis. This idea was further supported by gastric
cancer cell adhesion assay that showed TGF-b1-treated
peritonea were more favorable for gastric cancer cell
Figure 2 ELISA analysis of TGF-b1 protein levels in peritoneal wash fluid. Samples of the peritoneal wash fluid from patients with benign
disease and gastric cancer were obtained and subjected to ELISA analysis. The data were summarized as mean ± standard error of the mean
from at least 3 separate experiments. *p < 0.05 as compared with control.
Figure 3 Effects of TGF-b1 on expression of collagen III and fibronectin mRNA in HPMCs. Serum-starved HPMCs were incubated with
TGF-b1 (2 or 10 ng/ml) for up to 72 h and RNA was then isolated and subjected to semi-quantitative RT-PCR analysis of collagen III (A) and
fibronectin (B). Expression of b-actin was used as a loading control.
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TGF-b1 were closely related to the degree of peritoneal
fibrosis in gastric cancer patients (Stage III and IV gas-
tric cancers had high levels of TGF-b1 in the peritoneal
wash fluid, but also had more extensive peritoneal fibro-
sis). The data suggested that TGF-b1s e c r e t e db yg a s t r i c
cancer cells was able to promote peritoneal fibrosis and
in turn provide suitable ‘soil’ for metastasis.
In order to confirm the effect of TGF-b1 on peritoneal
fibrosis, we showed that TGF-b1 affected the function of
mesothelial cells by stimulating extracellular matrix
(including fibronectin and collagen III) production,
which consists of molecules important in cell adhesion
and tissue repair [24,25]. TGF-b1 induced fibronectin
and collagen III expression in both dose- and time-
dependent manners. Meanwhile, immunolocalization
showed that expression of fibronectin protein was
induced by TGF-b1 in HPMCs. These data further sup-
ported the central role theory for TGF-b1 in peritoneal
fibrosis and may provide a useful model by which to
study peritoneal metastasis of gastric cancer.
It is well known that TGF/Smad pathway can regulate
multiple cellular functions including inhibition and sti-
mulation of cell growth, cell death or apoptosis and
Figure 4 Western blot analysis of collagen III and fibronectin protein levels in HPMCs with or without TGF-b1 treatment. Serum-starved
HPMCs were incubated with increasing concentrations of TGF-b1 for up to 72 h and total cellular protein was extracted and subjected to
western blot analysis. A, Dose response of collagen III expression. B, Time course of collagen III expression. C, Dose response of fibronectin
expression. D, Time course of fibronectin expression.
Figure 5 Confocal immunofluorescence of fibronectin expression in mesothelial cells. Serum-starved HPMCs were incubated with TGF-b1
for up to 72 h, and fixed for immunostaining with a polyclonal antibody against fibronectin. Fibronectin was visualized by FITC (green), and
nuclei were visualized by To-PRO-3 (blue) under immunofluorescence confocal microscopy. A, Control cells. B, Mesothelial cells treated with
TGF-b1 (5 ng/ml) for 72 h. All photos were obtained at 100× magnification.
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demonstrated that TGF-b1 was able to induce Smad 2
and 3 phosphorylation in HPMCs. These data indicated
that rapid and sustained phosphorylation of Smad 2 and
Smad 3 may participate in TGF-b1-induced peritoneal
fibrosis.
Many studies have investigated the impact of the can-
cer-stroma interaction in different human cancers and
shown the importance of tumor cell interaction with
extracellular matrix to establish a favorable microenvir-
onment for tumor cell growth, invasion, and metastasis
[18,29,30]. Our data from the current study confirmed
such an interaction, in that TGF-b1 secreted by gastric
cancer cells was able to increase production of fibronec-
t i na n dc o l l a g e nI I Ii nH P M C sa n di nt u r ni n d u c ep e r i -
toneal fibrosis. TGF-b1-treated mesothelial cells affected
gastric cancer cell adhesion. We also determined
whether these effects are ECM-dependent by using RGD
to achieve selective and specific knockdown of minimal
sites of ECM cell binding domain. We found that RGD
treatment significantly decreased the adhesive ability of
cancer cells to mesothelial cells. These data suggest that
peritoneal fibrosis may stimulate the adherence capabil-
ity of gastric cancer cells to the peritoneum, which is
consistent with previous reports showing that TGF-b1
enhanced tumor-mesothelial cell adhesion [31,32].
We have also noticed that the concentration of TGF-
b1 in the peritoneal wash fluid was lower than that to
use in vitro to treat mesothelial cells. It may the natural
differences between in vivo and in vitro experiments and
the latter is acute and artificial. In addition, some other
factors secreted by gastric cancer cells may also contri-
bute to the effect.
In conclusions, our current study characterized the
interaction of gastric cancer with peritoneal fibrosis and
determined that TGF-b1 plays a key role in induction of
peritoneal fibrosis, which in turn affected gastric cancer
adhesion and metastasis. Furthermore, the pretreatment of
cancer cells with RGD significantly inhibited the adhesion
of carcinoma cells. Taken together, our current data
demonstrated that the presence of peritoneal fibrosis
appears to provide a favorable environment for dissemina-
tion of gastric cancer.
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